Skip to content

What is the development and course of paratonia in a group early stage dementia patients

What is the development and course of paratonia in a group early stage dementia patients - development of paratonia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON29942
Enrollment
100
Registered
2007-05-14
Start date
2006-10-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

counterpull Gegenhalten

Interventions

None listed

Sponsors

Universitair Medisch Centrum Sint Radboud
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: early stage dementie

Exclusion criteria

Exclusion criteria: a current active or progressive pathology that can influence their motor function (i.e. Multiple Sclerosis or Amyotrophic lateral sclerosis ect.). resistance or reluctance to participate

Design outcomes

Primary

MeasureTime frame
To assess the presence of paratonia all four limbs will be passively moved in flexion and extension with the participant in a sitting position. Paratonia is present when the assessors encounter all following 5 criteria during passive movement: * An involuntary variable resistance. * The degree of resistance varies depending on the speed of movement (e.g. a low resistance by slow movement and a high resistance by fast movement) * The resistance to passive movement can be in any direction * There is no clasp-knife phenomenon. * The resistance is in 2 movement direction in 1 limb or in 2 different limbs.

Secondary

MeasureTime frame
Timed up and Go test to assess the functional mobility [Podsiadlo et al., 1991] Qualidem for quality of life assessment [Ettema et al., 2005] Global deterioration Scale (GDS) and Mini Mental State examination (MMSE) to assess the severity of the dementia. Diagnosis of the dementia, the presence of cardio-vascular disease, m.Parkinson, Diabetes Mellitus and the use of neuroleptic medication will be obtained from the participants medical dossier.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)